ArticleBrain sciences2021
Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer's Disease.
Article in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- A Fluorescence-Based Acetylcholinesterase Inhibition Assay for Bioactivity-Guided Identification of Neuroactive Protoberberine Alkaloids fromMolecules (Basel, Switzerland) · 2026Article
- Compositional Studies and Bioactivity-Guided Fractionation of Acetylcholinesterase Inhibitors inMolecules (Basel, Switzerland) · 2026Article
- PROTAC-mediated multi-target protein degradation in Alzheimer's disease: mechanistic insights, therapeutic applications, and translational challenges.RSC medicinal chemistry · 2026Review
- Evaluating the Neuroprotective and Acetylcholinesterase Inhibitory Properties of Four Calcineurin Inhibitor Drugs: Tacrolimus, Pimecrolimus, Cyclosporin A, and Voclosporin.Molecular neurobiology · 2025Article
- Donepezil and Memantine Derivatives for Dual-Function and Prodrug Applications in Alzheimer's Disease.ACS chemical neuroscience · 2025Article
- Characterization of the Anticholinesterase and Antioxidant Properties of Phytochemicals fromBiomedicines · 2025Article
- Potential Applications of Natural Components of Traditional Chinese Medicine Delivery via Nanoparticle Drug Delivery Systems in the Treatment of Alzheimer's Disease.International journal of nanomedicine · 2025Review
- Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease.Heliyon · 2024Review
- Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.Signal transduction and targeted therapy · 2024Review
- Acai Berry (Life (Basel, Switzerland) · 2023Article
- Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer's Disease.International journal of molecular sciences · 2023Review
- Application of Marine Natural Products against Alzheimer's Disease: Past, Present and Future.Marine drugs · 2023Review
- Novel Dual AChE and ROCK2 Inhibitor Induces Neurogenesis via PTEN/AKT Pathway in Alzheimer's Disease Model.International journal of molecular sciences · 2022Article
- Therapeutic Potential of Targeting Mitochondria for Alzheimer's Disease Treatment.Journal of clinical medicine · 2022Review
- A Preliminary Assessment of the Nutraceutical Potential of Acai Berry (Molecules (Basel, Switzerland) · 2022Article
- In Silico Design of Dual-Binding Site Anti-Cholinesterase Phytochemical Heterodimers as Treatment Options for Alzheimer's Disease.Current issues in molecular biology · 2021Article
- A ratiometric fluorescence strategy based on inner filter effect for CuMikrochimica acta · 2021Article
- Effect of Water Extract of Mangosteen Pericarp on Donepezil Pharmacokinetics in Mice.Molecules (Basel, Switzerland) · 2021Article
- Secoyanhusamine A, an Oxidatively Ring-Opened Isoquinoline Inner Salt FromFrontiers in chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Alzheimer's disease (AD) is a burgeoning social and healthcare problem. Cholinesterase inhibitors (ChEIs) are employed for symptomatic treatment of AD, but often elicit adverse drug reactions (ADRs). Herein, the potency of the ChEIs, donepezil, tacrine, berberine, and galantamine to inhibit human or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.